Soon Printing a Human Heart on Demand Will No Longer Be Sci-Fi

January 25, 2017

(CNBC) – Imagine being able to grow a liver in a laboratory from cells and tissue for a transplant patient. Or engineering cells to grow into a heart valve to replace one damaged from heart disease. Around the world, start-ups — like Tokyo-based Cyfuse Biomedical — are emerging to develop such breakthroughs in the field of regenerative medicine. It is a market projected to reach $101.3 billion by 2022. Unlike conventional medicines and treatments, regenerative medicines have the ability to restore or heal the body’s own cells or create new body parts from a patient’s own cells and tissues, thereby eliminating tissue rejection and the excessively long wait for a donor organ.

Recommended Reading